Abstract
Objective: CHF is the inevitable outcome of all cardiovascular disease as CAD and AH. The morbidity of CHF is only 3.1 %, but at age more than 70 years, it is above 10 %. The treatment of CHF due to CAD and AH should include as first-line therapy beta-blockers or ivabradine, ACE inhibitors or ARBs with diuretics, nitrates with hydralazine (for African Americans). Amlodipine could be reserve drug in contraindications of beta-blockers or ivabradine. The additional treatment should include Aldosterone antagonists, non-dihydropyridine CCBs or Amiodarone, Digoxin as ’therapy of despair’, Aspirin, Statins, Omega-3 polyunsaturated acids. The purpose of our research was to analyze practical doctor's prescriptions for patients with CHF on base of CAD and AH. Design and method: We have studied 57 case history of patient with CHF, CAD and AH from one of therapeutic hospital in Ukraine. Doctor's prescriptions were analyzed according to modern guidelies. There are no cases of African patients. Results: Beta-blockers were prescribed to 41 patents (71.92 %), in 2 cases (3.51 %) it was non-selective one. ACE inhibitors were prescribed to 33 patients (57.89 %), ARBs to 22 (38.60 %), diuretics to 20 (35.09 %), nitrates to 6 (10.53 %), Hydralasin to no one. Dihydropyridine CCBs were in 5 cases (8.77 %), 3 of them (5.26 %) Amlodipine and 2 (3.51 %) Nifedipine. Non-dihydropyridine CCBs (Verapamil) were met in 2 cases (3.51 %). Cardiac glycoside have received 5 patients (8.77 %), 3 of them (5.26 %) digoxin, and rest sol. Corgliconi. ASA were prescribed to 40 patients (70.17 %), Statins only to 2 persons (3.51 %). Ivabradine, Amiodaron, Omega-3 polyunsaturated acids doctors have not prescribed. Patients have received 5.83 ± 1.02 drugs for treatment of CHF in average. But, there were metabolic, sedative, other drugs in case history, that were increased the number of prescriptions till 10.10 ± 2.16. Conclusions: The therapy of particular patient with CHF on base of CAD and AH should minimizing the amount of prescription drugs through the correct use of clinical pharmacological aspects of active ingredients, avoiding prescription drugs that are contraindicated in this case.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
